Drug profile · INN
methyldopa
ALDOMET
methyldopa (ALDOMET) is a adrenergic receptor alpha-2 agonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — methyldopa
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
methyldopa (ALDOMET) is a adrenergic receptor alpha-2 agonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha-2 agonist
Primary target: Adrenergic receptor alpha-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is methyldopa?
methyldopa (ALDOMET) is a adrenergic receptor alpha-2 agonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for methyldopa?
ALDOMET is a marketed brand name for methyldopa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methyldopa?
methyldopa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.